ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2013437-42ometendo-6389Research ArticleСтатьиArticlesВторичное ожирениеSecondary obesity. Part 2BabarinaM B

к.м.н., ст.н.с. отделения терапии эндокринопатий лечебно-диагностического отдела

endocrin@mail.ruFadeevaM I

н.с. отделения терапии эндокринопатий лечебно-диагностического отдела

fm2004@bk.ruSavelievaL V

к.м.н., зав. отделением терапии эндокринопатий лечебно-диагностического отдела

larisa.savelieva@inbox.ru201315122013104№4 (2013)3742Copyright © Babarina M.B., Fadeeva M.I., Savelieva L.V., 20132013Babarina M.B., Fadeeva M.I., Savelieva L.V.Babarina M.B., Fadeeva M.I., Savelieva L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6389

Глюкокортикоиды, пролактин и соматотропный гормон играют важную роль в регуляции метаболического гомеостаза. Гиперкортицизм, гиперпролактинемия и дефицит гормона роста приводят к увеличению массы тела за счет висцерального жира с преимущественным его перераспределением по абдоминальному типу. Механизмы развития ожирения при различных эндокринопатиях неодинаковы. Адекватная коррекция гормональных нарушений, как правило, сопровождается снижением массы тела и улучшением метаболических показателей.

Glucocorticoids, prolactin and growth hormone play an important role in the regulation of metabolic homeostasis. Hypercortisolism, hyperprolactinemia and growth hormone deficiency lead to an increase in body weight due to visceral fat accumulation. Mechanisms of development of obesity in various endocrine diseases are different. Adequate correction of hormonal disorders usually is accompanied by a decrease in body weight and the improvement of metabolic parameters.

ожирениекортизолпролактинсоматотропный гормонobesitycortisolprolactingrowth hormoneReferencesНейроэндокринология. Клинические очерки. Под редакцией Е.И. Маровой. Ярославль: «ДИА-пресс», 1999.Нейроэндокринология. Клинические очерки. Под редакцией Е.И. Маровой. Ярославль: «ДИА-пресс», 1999.Ожирение: этиология, патогенез, клинические аспекты. Руководство для врачей. Под редакцией И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агентство», 2004Ожирение: этиология, патогенез, клинические аспекты. Руководство для врачей. Под редакцией И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агентство», 2004Курляндская Р.М., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч. Врач. 2004; 1: 73–74.Курляндская Р.М., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч. Врач. 2004; 1: 73–74.Ahima R.S. (ed.) Metabolic basis of obesity. Springer Science + Business Media. LLC 2011; 139–154.Ahima R.S. (ed.) Metabolic basis of obesity. Springer Science + Business Media. LLC 2011; 139–154.Amato G., Carella C., Fazio S. et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J of Clin Endocrinol and Metabolism. 1993; 77(6): 1671–6.Amato G., Carella C., Fazio S. et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J of Clin Endocrinol and Metabolism. 1993; 77(6): 1671–6.Ben-Johantan N.,LaPense ChR, LaPense EW. What can we learn from rodents about prolactin with humans? Endocrine Reviews. 2008; 29 (1): 1–41.Ben-Johantan N.,LaPense ChR, LaPense EW. What can we learn from rodents about prolactin with humans? Endocrine Reviews. 2008; 29 (1): 1–41.Binnerts A., Deurenberg P., Roel Swart G., Paul Wilson JH., WJ Lamberts S. Body composition in growth hormone-deficient adults.Am J Clin Nutr. 1992; 55: 918–23.Binnerts A., Deurenberg P., Roel Swart G., Paul Wilson JH., WJ Lamberts S. Body composition in growth hormone-deficient adults.Am J Clin Nutr. 1992; 55: 918–23.Findling J.W., Raff H. Screening and diagnosis Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 2001; 30(3): 729–47.Findling J.W., Raff H. Screening and diagnosis Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 2001; 30(3): 729–47.Glynn N., Agha A. Diagnosing growth hormone deficiency in adults. Int J Endocrinol. 2012; Article ID 972617, 7.Glynn N., Agha A. Diagnosing growth hormone deficiency in adults. Int J Endocrinol. 2012; Article ID 972617, 7.Hans de Boer, Geert-Jan Blok, Eduard A. van der Veen Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews. 1995; 16(1): 63–86.Hans de Boer, Geert-Jan Blok, Eduard A. van der Veen Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews. 1995; 16(1): 63–86.Kadiolgu P.,Tirikiolgu O. et al. Screening for Cushing’s syndrome in obese is it really necessary? Presented at the Endocrine Society Meeting. New Orleans, 2004.Kadiolgu P.,Tirikiolgu O. et al. Screening for Cushing’s syndrome in obese is it really necessary? Presented at the Endocrine Society Meeting. New Orleans, 2004.Kok P, Roelfsema F, Frolicb M et al. Activation of Dopamine D2 Receptors Lowers Circadian Leptin Concentrations in Obese Women. Journal of Clinical Endocrinology & Metabolism. 2006; 81 (8): 3236–40.Kok P, Roelfsema F, Frolicb M et al. Activation of Dopamine D2 Receptors Lowers Circadian Leptin Concentrations in Obese Women. Journal of Clinical Endocrinology & Metabolism. 2006; 81 (8): 3236–40.Kok P., Roelfsema F., Frolich M. et al. Release is enhanced in proportion to excess visceral fat in obese woman. Journal of clinical Endocrinology & Metabolism. 2004; 89(9): 4445–9.Kok P., Roelfsema F., Frolich M. et al. Release is enhanced in proportion to excess visceral fat in obese woman. Journal of clinical Endocrinology & Metabolism. 2004; 89(9): 4445–9.Naef L, Woodside B. Prolactin/Leptin Interactions in the Control of Food Intake in Rats. Endocrinology. 2007; 148 (12): 5977–83.Naef L, Woodside B. Prolactin/Leptin Interactions in the Control of Food Intake in Rats. Endocrinology. 2007; 148 (12): 5977–83.Neiman L., Biller B., Finding J. et al. The diagnosis of the Cushing’s syndrome : An Endocrine Society Clinical Practice Guidline. J.Clin.Metab. 2008; 93(5): 1526–40.Neiman L., Biller B., Finding J. et al. The diagnosis of the Cushing’s syndrome : An Endocrine Society Clinical Practice Guidline. J.Clin.Metab. 2008; 93(5): 1526–40.Rask E., Olson.T, Soderberg S. Tissue-specific dysregulation of cortisol metabolism in human obesity. J.Clin.Metab. 2001; 86: 1418–21.Rask E., Olson.T, Soderberg S. Tissue-specific dysregulation of cortisol metabolism in human obesity. J.Clin.Metab. 2001; 86: 1418–21.Reynolds R.M.,Walker B.R. Human insulin resistance: the role of glucocorticoids. Diab.Obes.Metab 2003; 5–12.Reynolds R.M.,Walker B.R. Human insulin resistance: the role of glucocorticoids. Diab.Obes.Metab 2003; 5–12.Schid G, Goede D.L., Hauser R.S,Brandle M. Increased prevalence of high body mass index in patients presenting with pituitary tumors : severe obesity with macroprolactinoma. Swiss Med Wrly. 2006; 136: 254–8.Schid G, Goede D.L., Hauser R.S,Brandle M. Increased prevalence of high body mass index in patients presenting with pituitary tumors : severe obesity with macroprolactinoma. Swiss Med Wrly. 2006; 136: 254–8.Weaver J.U. Classical endocrine diseases causing obesity. Korbonits M (ed): Obesity and Metabolizm. Front Horm Res. Basel, Karger. 2008; 36: 212–228.Weaver J.U. Classical endocrine diseases causing obesity. Korbonits M (ed): Obesity and Metabolizm. Front Horm Res. Basel, Karger. 2008; 36: 212–228.Weaver JU, Noonan K, John WG, Edwards A, Evans KA, Cunningham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hipopituitary adults. J Clin Endocrinol Metab. 1995; 80(1): 153–9.Weaver JU, Noonan K, John WG, Edwards A, Evans KA, Cunningham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hipopituitary adults. J Clin Endocrinol Metab. 1995; 80(1): 153–9.

The authors declare that there are no conflicts of interest present.